Table 2. Rates of FN associated with the use of adjuvant FEC-T chemotherapy in high-risk node-positive patients with early breast cancer: a UK perspective (Head et al, 2008).

Data audited	Patients audited	Audit findings	Recommendation	Plan to re-audit
FN rate	137	25%	Primary G-CSF should be used throughout treatment with FEC-T	Following introduction of primary prophylaxis with G-CSF
Dose delays		25/137 (18.2%)
Dose reductions		27/137 (19.7%)
Use of primary G-CSF		30 patients
FN rate after primary G-CSF		2/30 (8.5%)
Use of secondary G-CSF		25%
FN rate after secondary G-CSF		0